Source BioScience PLC Extension of PUSU Deadline (8974C)
01 Juillet 2016 - 8:00AM
UK Regulatory
TIDMSBS
RNS Number : 8974C
Source BioScience PLC
01 July 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION.
Source BioScience plc
("Source BioScience" or the "Company")
Extension of PUSU Deadline
On 3 June 2016, the Board of Source BioScience announced that it
had received an approach from Continental Investment Partners SA
("Continental") and Harwood Capital LLP ("Harwood Capital")
(together, the "Joint Offerors") which may or may not lead to an
offer being made to acquire the entire issued and to be issued
ordinary share capital of the Company at 18 pence per ordinary
share of 2 pence each in the capital of Source BioScience (the
"Possible Offer").
The announcement stated that any announcement of a Firm Offer in
accordance with Rule 2.7 of the Code would be subject to, amongst
other things, a deadline of 5.00pm (UK time) on 1 July 2016 (the
"PUSU Deadline").
Discussions with the Joint Offerors are ongoing and the Board of
Source BioScience has requested that the Panel extend the PUSU
Deadline. In the light of this request, an extension has been
granted by the Panel and in accordance with Rule 2.6(a) of the Code
the Joint Offerors must, by no later than 5.00pm (UK time) on 29
July 2016, either announce a Firm Offer or announce that it does
not intend to make an offer for the Company, in which case the
announcement will be treated as a statement to which Rule 2.8 of
the Code applies.
There can be no certainty that the Joint Offerors will proceed
to make a Firm Offer for the Company. This statement is being made
with the agreement of the Joint Offerors. Further announcements
will be made in due course.
Enquiries:
Source BioScience plc Tel. +44 (0)
Laurie Turnbull 115 973 9010
Dr Nick Ash
N+1 Singer (Financial Advisor Tel. +44 (0)
to Source BioScience) 20 7496 3000
Nic Hellyer
James White
Nplus1 Singer Advisory LLP ("N+1 Singer"), which is authorised
and regulated in the United Kingdom by the Financial Conduct
Authority, is acting exclusively for the Company as financial
advisor and broker in relation to the Possible Offer and is not
acting for any other person in relation to such Possible Offer. N+1
Singer will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing
advice in relation to the contents of this announcement or any
Possible Offer or any other arrangement referred to herein.
Disclosure requirements of the Code:
Under Rule 8.3(a) of the Code, any person who is interested in
1% or more of any class of relevant securities of Source BioScience
or of any securities exchange offeror (being any offeror other than
an offeror in respect of which it has been announced that its offer
is, or is likely to be, solely in cash) must make an Opening
Position Disclosure following the commencement of the offer period
and, if later, following the announcement in which any securities
exchange offeror is first identified. An Opening Position
Disclosure must contain details of the person's interests and short
positions in, and rights to subscribe for, any relevant securities
of each of (i) Source BioScience and (ii) any securities exchange
offeror(s). An Opening Position Disclosure by a person to whom Rule
8.3(a) applies must be made by no later than 3.30 p.m. (London
time) on the 10th business day following the commencement of the
offer period and, if appropriate, by no later than 3.30 p.m.
(London time) on the 10th business day following the announcement
in which any securities exchange offeror is first identified.
Relevant persons who deal in the relevant securities of Source
BioScience or of a securities exchange offeror prior to the
deadline for making an Opening Position Disclosure must instead
make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes,
interested in 1% or more of any class of relevant securities of
Source BioScience or of any securities exchange offeror must make a
Dealing Disclosure if the person deals in any relevant securities
of Source BioScience or of any securities exchange offeror. A
Dealing Disclosure must contain details of the dealing concerned
and of the person's interests and short positions in, and rights to
subscribe for, any relevant securities of each of (i) Source
BioScience and (ii) any securities exchange offeror(s), save to the
extent that these details have previously been disclosed under Rule
8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies
must be made by no later than 3.30 p.m. (London time) on the
business day following the date of the relevant dealing.
If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire or control an
interest in relevant securities of Source BioScience or a
securities exchange offeror, they will be deemed to be a single
person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by Source
BioScience and by any offeror and Dealing Disclosures must also be
made by Source BioScience, by any offeror and by any persons acting
in concert with any of them (see Rules 8.1, 8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose
relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table on
the Takeover Panel's website at www.thetakeoverpanel.org.uk,
including details of the number of relevant securities in issue,
when the offer period commenced and when any offeror was first
identified. You should contact the Panel's Market Surveillance Unit
on +44 (0)20 7638 0129 if you are in any doubt as to whether you
are required to make an Opening Position Disclosure or a Dealing
Disclosure.
This announcement does not constitute an offer to purchase any
securities, or an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any offer to purchase or
sell securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful. The release, distribution
or publication of this announcement in jurisdictions other than the
UK may be restricted by law and therefore any persons who are
subject to the laws of any jurisdiction other than the UK should
inform themselves about and observe any applicable
requirements.
Publication on website
A copy of this announcement will be made available (subject to
certain restrictions relating to persons resident in restricted
jurisdictions) on the Source BioScience plc website at
www.sourcebioscience.com by no later than 12 noon (London time) on
the business day following this announcement.
For the avoidance of doubt, the content of the website referred
to above is not incorporated into and does not form part of this
announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSDIFWSFMSEDM
(END) Dow Jones Newswires
July 01, 2016 02:00 ET (06:00 GMT)
Source Bioscience (LSE:SBS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Source Bioscience (LSE:SBS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024